Physician profile
Carl Raso
NPI 1306934195
$4,817.76
in general payments reported to CMS, 2019-2025
34 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $627 · 2021: $749 · 2022: $749 · 2023: $752 · 2024: $924 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.99 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,235.24 | 2019-2025 | |
| Janssen Biotech, INC. | $927.74 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $457.48 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.31 | 2019-2024 | Xifaxan, Plenvu |
| Nestle Healthcare Nutrition INC. | $206.41 | 2020-2023 | |
| Celgene Corporation | $189.03 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $176.60 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $121.09 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $113.06 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $103.57 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $101.79 | 2020-2025 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $93.06 | 2021 | |
| Boston Scientific Corporation | $82.55 | 2020 | |
| Genzyme Corporation | $80.93 | 2022-2025 | |
| Concordia Pharmaceuticals INC. | $57.55 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44.10 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $43.86 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $43.05 | 2024 | Iqirvo |
| Qol Medical, LLC | $41.15 | 2023 | Sucraid |
| Allergan, INC. | $39.57 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $38.39 | 2024 | |
| Celltrion USA INC. | $35.31 | 2024-2025 | Vegzelma |
| Pfizer INC. | $31.24 | 2023-2025 | |
| Alfasigma USA, INC. | $28.15 | 2020-2021 | |
| Lilly USA, LLC | $23.14 | 2024 | Omvoh |
| Exact Sciences Corporation | $22.54 | 2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $20.59 | 2024 | Resmetirom |
| Olympus America INC. | $20.57 | 2024 | Evis Exera III Colonovideoscope |
| Aimmune Therapeutics, INC. | $16.59 | 2024 | |
| Intra-Sana Laboratories | $15.86 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Daiichi Sankyo INC. | $13.75 | 2019 | |
| Shire North American Group INC | $12.50 | 2019 | |
| Romark Laboratories, Lc | $12.50 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Raso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.